NRX Pharmaceuticals

NRx Pharmaceuticals and its subsidiary HOPE Therapeutics signed a definitive agreement to acquire Kadima Neuropsychiatry Institute, a leading interventional psychiatry clinic in La Jolla, California.

NRx Pharmaceuticals is developing NRX-101, an FDA-designated Breakthrough Therapy for treatment-resistant bipolar depression with suicidality, with plans to file for Accelerated Approval.

• The global bipolar depression market is projected to experience significant growth through 2034, driven by increasing prevalence, with the United States accounting for approximately 85% of the market share across major regions. • Several pharmaceutical companies including NeuroRx, COMPASS Pathways, and Intra-Cellular Therapies are advancing novel treatments, with Johnson & Johnson's recent $14.6 billion acquisition of Intra-Cellular Therapies highlighting industry confidence in the sector. • Among current therapies, CAPLYTA (lumateperone) is expected to achieve the highest market share by 2034, while emerging treatments like NRX-100/101 and COMP 360 (psilocybin) show promise for addressing unmet needs in bipolar depression management.

NRx Pharmaceuticals subsidiary HOPE Therapeutics announces planned acquisition of Kadima Neuropsychiatry Institute to serve as the flagship for an international network of interventional psychiatry clinics treating depression and PTSD.

HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals, has signed a definitive agreement to acquire Dura Medical, an EBITDA-positive provider of interventional psychiatry services in Florida.

NRx Pharmaceuticals has filed the initial section of its New Drug Application (NDA) to the FDA for NRX-100 (ketamine) to treat suicidal depression.

NRx Pharmaceuticals' methodology for training and monitoring study site raters demonstrates higher interrater reliability (IRR) on the MADRS depression scale.

NRx Pharmaceuticals' novel training and monitoring methodology demonstrated a 94.5% interrater reliability in a Phase 2b/3 clinical trial for NRX-101, surpassing previous industry standards.

NRx Pharmaceuticals is on track to file NDAs for NRX-100 (IV Ketamine) and NRX-101 (Oral D-Cycloserine/Lurasidone) by year-end 2024 for treating suicidal ideation and bipolar depression.

NRx Pharmaceuticals is on track to file NDAs for NRX-100 (IV Ketamine) for suicidal ideation in depression and NRX-101 (Oral D-Cycloserine/Lurasidone) for bipolar depression with suicidality by year-end 2024.